October 28, 2020 -- Arena Pharmaceuticals has launched Longboard Pharmaceuticals with $56 million in financing to support the development of the company's lead clinical and preclinical programs.
LP352 is a next-generation 5-HT2C agonist and a clinical stage program for treatment-resistant developmental and epileptic encephalopathies. Preclinical programs relating to LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor, and LP659, a centrally acting, next-generation highly selective sphingosine 1-phosphate receptor modulator, are also being developed for the potential treatment of microglial neuroinflammatory diseases.
The new company will be focused on the development of novel central nervous system-targeted assets discovered by Arena's validated G protein-coupled receptor research engine.
Longboard, formerly known as Arena Neuroscience, was a wholly owned subsidiary of Arena Pharmaceuticals.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
